Overview
Mustafa Hammudi is a primary care provider, practicing in Hematologist Oncology in Washington, Washington, D.c.. His top area of expertise is Systemic Capillary Leak Syndrome. Dr. Hammudi is currently accepting new patients.
His clinical research consists of co-authoring 3 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Graduate Institution
Specialties
Licenses
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is highly rated in 16 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.
Maryland Oncology Hematology
As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is highly rated in 43 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.
Frederick P Smith MD A Division Of RCCA
Dr. Frederick P. Smith is a medical oncologist specializing in breast cancer at Sibley Memorial Hospital and an instructor at Johns Hopkins School of Medicine and Georgetown University School of Medicine. He has a private practice in Washington, D.C. He is affiliated with Sibley Memorial Hospital and Suburban Hospital. Dr. Smith earned his medical degree from Saint Louis University School of Medicine. He completed a residency in internal medicine at Georgetown University Hospital, followed by a fellowship in oncology. Dr. Smith was named a 2012 Top Doctor in the Washington, D.C., Baltimore and Washington-Baltimore areas by Castle Connolly, as well as a Top MD by Consumers’ Checkbook Magazine. Prior to joining Johns Hopkins, Dr. Smith was the director of extramural oncology research at Georgetown University. In this position, he contributed over 50 articles to peer-reviewed medical journals. Dr. Smith is an integral advocate in the community for promoting access to clinical research. He has also contributed to clinical trials. Dr. Smith is highly rated in 25 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma.
Frequently Asked Questions about Dr. Mustafa Hammudi
How do I make an appointment with Dr. Mustafa Hammudi?
You can book an appointment with Dr. Mustafa Hammudi by calling their office at 202-715-5109. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Mustafa Hammudi a top-rated expert for Systemic Capillary Leak Syndrome?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mustafa Hammudi is classified as an Experienced expert for Systemic Capillary Leak Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Mustafa Hammudi specialize in?
While Dr. Mustafa Hammudi is a Hematology Oncology, they have specific expertise in Systemic Capillary Leak Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.
Does Dr. Mustafa Hammudi participate in research or clinical trials?
Yes. Dr. Mustafa Hammudi has published 3 articles and abstracts on conditions like Systemic Capillary Leak Syndrome. You can view a list of Dr. Mustafa Hammudi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Mustafa Hammudi accept my insurance?
Dr. Mustafa Hammudi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 202-715-5109 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Systemic Capillary Leak SyndromeDr. Hammudi isExperienced. Learn about Systemic Capillary Leak Syndrome.

